Literature DB >> 31515462

Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.

Anne-Sophie Hamy1,2, Hélène Bonsang-Kitzis1,3, Marick Laé4, Fabien Reyal5,3,6, Diane De Croze7, Enora Laas3, Lauren Darrigues3, Lucian Topciu4, Emmanuelle Menet7, Anne Vincent-Salomon4, Florence Lerebours8, Jean-Yves Pierga2,6, Etienne Brain8, Jean-Guillaume Feron3, Gabriel Benchimol3, Giang-Thanh Lam3,9.   

Abstract

PURPOSE: High levels of tumor-infiltrating lymphocytes (TIL) before neoadjuvant chemotherapy (NAC) are associated with higher pathologic complete response (pCR) rates and better survival in triple-negative breast cancer (TNBC) and HER2-positive breast cancer. We investigated the value of TIL levels by evaluating lymphocyte infiltration before and after NAC. EXPERIMENTAL
DESIGN: We assessed stromal TIL levels in 716 pre- and posttreatment matched paired specimens, according to the guidelines of the International TIL Working Group.
RESULTS: Pre-NAC TIL levels were higher in tumors for which pCR was achieved than in cases with residual disease (33.9% vs. 20.3%, P = 0.001). This was observed in luminal tumors and TNBCs, but not in HER2-positive breast cancers (P Interaction = 0.001). The association between pre-NAC TIL levels and pCR was nonlinear in TNBCs (P = 0.005). Mean TIL levels decreased after chemotherapy completion (pre-NAC TILs: 24.1% vs. post-NAC TILs: 13.0%, P < 0.001). This decrease was strongly associated with high pCR rates, and the variation of TIL levels was strongly inversely correlated with pre-NAC TIL levels (r = -0.80, P < 0.001). Pre-NAC TILs and disease-free survival (DFS) were associated in a nonlinear manner (P < 0.001). High post-NAC TIL levels were associated with aggressive tumor characteristics and with impaired DFS in HER2-positive breast cancers (HR, 1.04; confidence interval, 1.02-1.06; P = 0.001), but not in luminal tumors or TNBCs (P Interaction = 0.04).
CONCLUSIONS: The associations of pre- and post-NAC TIL levels with response to treatment and DFS differ between breast cancer subtypes. The characterization of immune subpopulations may improve our understanding of the complex interactions between pre- or post-NAC setting, breast cancer subtype, response to treatment, and prognosis. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31515462     DOI: 10.1158/1078-0432.CCR-18-3017

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

Review 1.  The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas.

Authors:  Laura Annaratone; Eliano Cascardi; Elena Vissio; Ivana Sarotto; Ewa Chmielik; Anna Sapino; Enrico Berrino; Caterina Marchiò
Journal:  Pathobiology       Date:  2020-04-23       Impact factor: 4.342

2.  Prognostic significance of the primary tumor site and immune indexes in patients with estrogen receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.

Authors:  Xinming Song; Jianli Ma; Han Zhang; Qingyuan Zhang
Journal:  Gland Surg       Date:  2020-10

3.  The neoadjuvant chemotherapy responses and survival rates of patients with different molecular subtypes of breast cancer.

Authors:  Hui Zhang; Xiaoyu Zhang; Lijun Jin; Zunyi Wang
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

4.  How the variability between computer-assisted analysis procedures evaluating immune markers can influence patients' outcome prediction.

Authors:  Marylène Lejeune; Benoît Plancoulaine; Nicolas Elie; Ramon Bosch; Laia Fontoura; Izar de Villasante; Anna Korzyńska; Andrea Gras Navarro; Esther Sauras Colón; Carlos López
Journal:  Histochem Cell Biol       Date:  2021-08-12       Impact factor: 4.304

5.  Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer.

Authors:  Soomin Ahn; Yul Ri Chung; An Na Seo; Milim Kim; Ji Won Woo; So Yeon Park
Journal:  PLoS One       Date:  2020-05-13       Impact factor: 3.240

6.  Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.

Authors:  Zhao-Hua Gao; Cun-Xin Li; Ming Liu; Jia-Yuan Jiang
Journal:  BMC Cancer       Date:  2020-11-25       Impact factor: 4.430

7.  Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer.

Authors:  Yiqun Han; Jiayu Wang; Binghe Xu
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

8.  The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.

Authors:  Wen-Juan Tian; Shan-Shan Liu; Bu-Rong Li
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

9.  Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.

Authors:  Beatriz Grandal; Clémence Evrevin; Enora Laas; Isabelle Jardin; Sonia Rozette; Lucie Laot; Elise Dumas; Florence Coussy; Jean-Yves Pierga; Etienne Brain; Claire Saule; Dominique Stoppa-Lyonnet; Sophie Frank; Claire Sénéchal; Marick Lae; Diane De Croze; Guillaume Bataillon; Julien Guerin; Fabien Reyal; Anne-Sophie Hamy
Journal:  Cancers (Basel)       Date:  2020-12-08       Impact factor: 6.639

10.  CircTMC5 promotes gastric cancer progression and metastasis by targeting miR-361-3p/RABL6.

Authors:  Peng Xu; XiaoLan Xu; Xiao Wu; LiXiang Zhang; Lei Meng; ZhangMing Chen; WenXiu Han; Jie Yao; AMan Xu
Journal:  Gastric Cancer       Date:  2021-07-22       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.